Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 884

1.

TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.

Jones RN, Moet GJ, Sader HS, Mendes RE, Castanheira M.

J Antimicrob Chemother. 2009 Apr;63(4):716-20. doi: 10.1093/jac/dkp021.

PMID:
19218276
2.

Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.

Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, Turnidge JD.

Diagn Microbiol Infect Dis. 2009 Dec;65(4):404-13. doi: 10.1016/j.diagmicrobio.2009.10.001.

PMID:
19913683
3.

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.

Livermore DM, Mushtaq S, Warner M, Woodford N.

J Antimicrob Chemother. 2009 Apr;63(4):713-5. doi: 10.1093/jac/dkp002.

PMID:
19164418
4.

Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe).

Bolmstrom A, Ballow CH, Qwarnstrom A, Biedenbach DJ, Jones RN.

Clin Microbiol Infect. 2002 Dec;8(12):791-800.

5.

Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.

Ross JE, Anderegg TR, Sader HS, Fritsche TR, Jones RN.

Diagn Microbiol Infect Dis. 2005 May;52(1):53-8.

PMID:
15878443
6.

Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific.

Bell JM, Turnidge JD, Ballow CH, Jones RN; ZAPS Regional Participants..

J Antimicrob Chemother. 2003 Feb;51(2):339-45.

PMID:
12562700
7.

A multicenter evaluation of linezolid antimicrobial activity in North America.

Ballow CH, Jones RN, Biedenbach DJ; North American ZAPS Research Group..

Diagn Microbiol Infect Dis. 2002 May;43(1):75-83.

PMID:
12052632
8.

Linezolid surveillance program results for 2008 (LEADER Program for 2008).

Farrell DJ, Mendes RE, Ross JE, Jones RN.

Diagn Microbiol Infect Dis. 2009 Dec;65(4):392-403. doi: 10.1016/j.diagmicrobio.2009.10.011.

PMID:
19913682
9.

Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.

Anderegg TR, Sader HS, Fritsche TR, Ross JE, Jones RN.

Int J Antimicrob Agents. 2005 Jul;26(1):13-21.

PMID:
15967640
10.

Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).

Fritsche TR, Sader HS, Stillwell MG, Jones RN.

Diagn Microbiol Infect Dis. 2009 Apr;63(4):440-6. doi: 10.1016/j.diagmicrobio.2009.01.019.

PMID:
19302928
11.

Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus.

Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Peláez B, Andrade R, de la Torre MA, Fereres J, Sánchez-García M.

Clin Infect Dis. 2010 Mar 15;50(6):821-5. doi: 10.1086/650574.

PMID:
20144045
12.
13.

Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.

Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN.

Diagn Microbiol Infect Dis. 2002 May;43(1):65-73.

PMID:
12052631
14.

Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods.

Muller-Serieys C, Drugeon HB, Etienne J, Lascols C, Leclercq R, Nguyen J, Soussy CJ.

Clin Microbiol Infect. 2004 Mar;10(3):242-6.

15.
16.

Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway.

Simonsen GS, Bergh K, Bevanger L, Digranes A, Gaustad P, Melby KK, Høiby EA.

Scand J Infect Dis. 2004;36(4):254-8.

PMID:
15198180
17.
18.

In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.

Schaadt R, Sweeney D, Shinabarger D, Zurenko G.

Antimicrob Agents Chemother. 2009 Aug;53(8):3236-9. doi: 10.1128/AAC.00228-09.

20.

Evaluation of the in vitro activity of tigecycline against multiresistant Gram-positive cocci containing tetracycline resistance determinants.

Borbone S, Lupo A, Mezzatesta ML, Campanile F, Santagati M, Stefani S.

Int J Antimicrob Agents. 2008 Mar;31(3):209-15.

PMID:
17646087

Supplemental Content

Support Center